Ventyx Biosciences’ (VTYX) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Ventyx Biosciences (NASDAQ:VTYX) in a report published on Thursday, Benzinga reports. They currently have a $6.00 price objective on the stock.

Other analysts have also recently issued research reports about the company. Oppenheimer reduced their price target on Ventyx Biosciences from $12.00 to $10.00 and set an outperform rating for the company in a research report on Thursday, June 6th. Lifesci Capital raised Ventyx Biosciences from a market perform rating to an outperform rating in a research report on Wednesday, February 28th. Wells Fargo & Company raised shares of Ventyx Biosciences from an equal weight rating to an overweight rating and lifted their price target for the company from $7.00 to $16.00 in a research report on Tuesday, March 12th. Finally, Canaccord Genuity Group decreased their price objective on shares of Ventyx Biosciences from $16.00 to $15.00 and set a buy rating for the company in a report on Wednesday, March 13th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $15.75.

Ventyx Biosciences Stock Performance

Shares of VTYX opened at $2.88 on Thursday. The firm has a market cap of $203.04 million, a PE ratio of -0.89 and a beta of 0.58. The firm’s 50 day moving average price is $4.36 and its 200 day moving average price is $4.10. Ventyx Biosciences has a twelve month low of $1.87 and a twelve month high of $40.58.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05. During the same quarter last year, the business posted ($0.68) EPS. On average, sell-side analysts anticipate that Ventyx Biosciences will post -2.31 earnings per share for the current fiscal year.

Institutional Trading of Ventyx Biosciences

A number of hedge funds have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Ventyx Biosciences by 139.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 63,944 shares of the company’s stock valued at $2,221,000 after purchasing an additional 37,240 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Ventyx Biosciences by 962.7% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 987,970 shares of the company’s stock worth $34,312,000 after acquiring an additional 895,000 shares during the period. Hudson Bay Capital Management LP boosted its position in shares of Ventyx Biosciences by 160.2% during the 3rd quarter. Hudson Bay Capital Management LP now owns 248,515 shares of the company’s stock valued at $8,631,000 after acquiring an additional 153,000 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Ventyx Biosciences by 42.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 363,385 shares of the company’s stock valued at $12,620,000 after acquiring an additional 107,997 shares in the last quarter. Finally, FMR LLC increased its stake in Ventyx Biosciences by 1.5% in the third quarter. FMR LLC now owns 8,677,529 shares of the company’s stock valued at $301,371,000 after acquiring an additional 124,298 shares during the period. 97.88% of the stock is owned by institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.